Efficacy of Tralokinumab for treatment of atopic dermatitis
Atopic dermatitis occurs when the barrier function of the skin is disrupted, allowing chemicals and allergens to enter the skin and cause inflammation. Tralokinumab is a drug injected under the skin that targets interleukin (IL) 13, a molecule that is important in causing the skin inflammation associated with atopic dermatitis.

Two identically designed clinical trials, ECZTRA 1 and ECZTRA 2, investigated if tralokinumab alone was more effective than a nonactive drug for improving the severity and symptoms of atopic dermatitis.

Adult patients who had moderate to severe atopic dermatitis for more than 1 year that had not improved sufficiently with topical treatments were included. Patients received tralokinumab 300 mg or placebo every 2 weeks for an initial 16 weeks. Patients who showed a good response to tralokinumab either continued with the same treatment, received less frequent dosing of tralokinumab (once every 4 weeks), or received placebo for a further 36 weeks to assess long term safety. The medical team also documented the occurrence of any side effects of the drug.

Results:
--In both trials at week 16, more patients receiving tralokinumab had an improvement in their atopic dermatitis compared with patients receiving placebo.

--Patients felt meaningful improvements in itch, sleep and quality of life as early as 1–2 weeks after starting tralokinumab.

--The majority of patients who had high levels of improvement at week 16 with tralokinumab maintained that level of improvement after another 36 weeks of treatment with dosing every 2 weeks.

--In addition, some patients maintained their improved skin with less frequent dosing every 4 weeks.

--The most common side effects with tralokinumab were upper respiratory tract infections (mainly common cold) and conjunctivitis (inflammation of the eye or eyelid).

In particular, Trolokinumab may be a long-term treatment choice for adult patients with mild to extreme atopic dermatitis, based on the findings of these studies.

Source: https://onlinelibrary.wiley.com/doi/10.1111/bjd.19778?af=R
Like
Comment
Share